Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer

Open access
Kurian, Allison W., Ward, Kevin C., Hamilton, Ann S., Deapen, Dennis M., Abrahamse, Paul, Bondarenko, Irina, Li, Yun, Hawley, Sarah T., Morrow, Monica, Jagsi, Reshma, Katz, Steven J. · 2018 · JAMA Oncology

Abstract

Importance: Low-cost sequencing of multiple genes is increasingly available for cancer risk assessment. Little is known about uptake or outcomes of multiple-gene sequencing after breast cancer diagnosis in community practice. Objective: To examine the effect of multiple-gene sequencing on the experience and treatment outcomes for patients with breast cancer. Design, Setting, and Participants: For this population-based retrospective cohort study, patients with breast cancer diagnosed from January 2013 to December 2015 and accrued from SEER registries across Georgia and in Los Angeles, California, were surveyed (n = 5080, response rate = 70%). Responses were merged with SEER data and results of clinical genetic tests, either BRCA1 and BRCA2 (BRCA1/2) sequencing only or including additional other genes (multiple-gene sequencing), provided by 4 laboratories. Main Outcomes and Measures: Type of testing (multiple-gene sequencing vs BRCA1/2-only sequencing), test results (negative, variant of unknown significance, or pathogenic variant), patient experiences with testing (timing of testing, who discussed results), and treatment (strength of patient consideration of, and surgeon recommendation for, prophylactic mastectomy), and prophylactic mastectomy receipt. We defined a patient subgroup with higher pretest risk of carrying a pathogenic variant according to practice guidelines. Results: Among 5026 patients (mean [SD] age, 59.9 [10.7] years), 1316 (26.2%) were linked to genetic results from any laboratory. Multiple-gene sequencing increasingly replaced BRCA1/2-only testing over time: in 2013, the rate of multiple-gene sequencing was 25.6% and BRCA1/2-only testing, 74.4%; in 2015 the rate of multiple-gene sequencing was 66.5% and BRCA1/2-only testing, 33.5%. Multiple-gene sequencing was more often ordered by genetic counselors (multiple-gene sequencing, 25.5% and BRCA1/2-only testing, 15.3%) and delayed until after surgery (multiple-gene sequencing, 32.5% and BRCA1/2-only testing, 19.9%). Multiple-gene sequencing substantially increased rate of detection of any pathogenic variant (multiple-gene sequencing: higher-risk patients, 12%; average-risk patients, 4.2% and BRCA1/2-only testing: higher-risk patients, 7.8%; average-risk patients, 2.2%) and variants of uncertain significance, especially in minorities (multiple-gene sequencing: white patients, 23.7%; black patients, 44.5%; and Asian patients, 50.9% and BRCA1/2-only testing: white patients, 2.2%; black patients, 5.6%; and Asian patients, 0%). Multiple-gene sequencing was not associated with an increase in the rate of prophylactic mastectomy use, which was highest with pathogenic variants in BRCA1/2 (BRCA1/2, 79.0%; other pathogenic variant, 37.6%; variant of uncertain significance, 30.2%; negative, 35.3%). Conclusions and Relevance: Multiple-gene sequencing rapidly replaced BRCA1/2-only testing for patients with breast cancer in the community and enabled 2-fold higher detection of clinically relevant pathogenic variants without an associated increase in prophylactic mastectomy. However, important targets for improvement in the clinical utility of multiple-gene sequencing include postsurgical delay and racial/ethnic disparity in variants of uncertain significance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2018.0644

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 33

  1. Katz, 2015, Treatment decision making and genetic testing for breast cancer: mainstreaming mutations., JAMA, 314, 997, 10.1001/jama.2015.8088 · DOI
  2. Samimi, 2017, Traceback: a proposed framework to increase identification and genetic counseling of brca1 and brca2 mutation carriers through family-based outreach., J Clin Oncol, 35, 2329, 10.1200/JCO.2016.70.3439 · DOI
  3. Domchek, 2013, Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?, J Clin Oncol, 31, 1267, 10.1200/JCO.2012.46.9403 · DOI · Paper page
  4. Offit, 2013, Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology., J Clin Oncol, 31, 2743, 10.1200/JCO.2013.49.7388 · DOI
  5. Kurian, 2015, Multigene panel testing in oncology practice: how should we respond?, JAMA Oncol, 1, 277, 10.1001/jamaoncol.2015.28 · DOI
  6. Hawley, 2017, Recurrence risk perception and quality of life following treatment of breast cancer., Breast Cancer Res Treat, 161, 557, 10.1007/s10549-016-4082-7 · DOI
  7. Jagsi, 2017, Treatment decisions and employment of breast cancer patients: Results of a population-based survey., Cancer, 123, 4791, 10.1002/cncr.v123.24 · doi:10.1002/cncr.v123.24
  8. Jagsi, 2017, Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer., JAMA Surg, 152, 274, 10.1001/jamasurg.2016.4749 · doi:10.1001/jamasurg.2016.4749
  9. Kurian, Recent trends in chemotherapy use and oncologists' treatment recommendations for early-stage breast cancer, J Natl Cancer Inst
  10. Kurian, 2017, Second opinions from medical oncologists for early-stage breast cancer: prevalence, correlates, and consequences., JAMA Oncol, 3, 391, 10.1001/jamaoncol.2016.5652 · DOI
  11. Kurian, 2017, Genetic testing and counseling among patients with newly diagnosed breast cancer., JAMA, 317, 531, 10.1001/jama.2016.16918 · DOI
  12. Kurian, 2017, Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer., J Clin Oncol, 35, 2232, 10.1200/JCO.2016.71.6480 · DOI · Paper page
  13. Richards, 2008, ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007., Genet Med, 10, 294, 10.1097/GIM.0b013e31816b5cae · DOI · Paper page
  14. Daly, 2017, NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017., J Natl Compr Canc Netw, 15, 9, 10.6004/jnccn.2017.0003 · DOI · Paper page
  15. Kurian, 2014, Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment., J Clin Oncol, 32, 2001, 10.1200/JCO.2013.53.6607 · DOI · Paper page
  16. Tung, 2015, Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel., Cancer, 121, 25, 10.1002/cncr.29010 · DOI · Paper page
  17. LaDuca, 2014, Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients., Genet Med, 16, 830, 10.1038/gim.2014.40 · DOI · Paper page
  18. Desmond, 2015, Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment., JAMA Oncol, 1, 943, 10.1001/jamaoncol.2015.2690 · DOI · Paper page
  19. Maxwell, 2015, Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer., Genet Med, 17, 630, 10.1038/gim.2014.176 · DOI · Paper page
  20. Thompson, 2016, Panel testing for familial breast cancer: calibrating the tension between research and clinical care., J Clin Oncol, 34, 1455, 10.1200/JCO.2015.63.7454 · DOI · Paper page
  21. Selkirk, 2014, Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice., Fam Cancer, 13, 527, 10.1007/s10689-014-9741-4 · DOI
  22. Couch, 2015, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer., J Clin Oncol, 33, 304, 10.1200/JCO.2014.57.1414 · DOI · Paper page
  23. Tung, 2016, Counselling framework for moderate-penetrance cancer-susceptibility mutations., Nat Rev Clin Oncol, 13, 581, 10.1038/nrclinonc.2016.90 · DOI · Paper page
  24. Delikurt, 2015, A systematic review of factors that act as barriers to patient referral to genetic services., Eur J Hum Genet, 23, 739, 10.1038/ejhg.2014.180 · DOI · Paper page
  25. Hall, 2009, BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer., Cancer, 115, 2222, 10.1002/cncr.24200 · DOI · Paper page
  26. Caswell-Jin, Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk., Genet Med
  27. Metcalfe, 2008, International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers., Int J Cancer, 122, 2017, 10.1002/ijc.23340 · DOI · Paper page
  28. Wainberg, 2004, Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation., Cancer Epidemiol Biomarkers Prev, 13, 1989, 10.1158/1055-9965.1989.13.12 · DOI
  29. Weitzel, 2003, Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis., Arch Surg, 138, 1323, 10.1001/archsurg.138.12.1323 · DOI
  30. Pal, 2013, A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer., Genet Test Mol Biomarkers, 17, 367, 10.1089/gtmb.2012.0381 · DOI · Paper page
  31. Atchley, 2008, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer., J Clin Oncol, 26, 4282, 10.1200/JCO.2008.16.6231 · DOI · Paper page
  32. Ladabaum, 2011, Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis., Ann Intern Med, 155, 69, 10.7326/0003-4819-155-2-201107190-00002 · DOI · Paper page
  33. Dillman, 2009, Internet, Mail, and Mixed-Mode Surveys: The Tailored Design Method

Cited by

See all 193

Metadata

Authors
Kurian, A. W., Ward, K. C., Hamilton, A. S., Deapen, D. M., Abrahamse, P., Bondarenko, I., Li, Y., Hawley, S. T., Morrow, M., Jagsi, R., & Katz, S. J.
Venue
JAMA Oncology
Published
2018-08-01
Volume
4
Issue
8
Pages
1066
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2802287528
Cited by
193
References
3
FWCI
13.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. https://app.cochat.ai/papers/10.1001/jamaoncol.2018.0644
The paper
Kurian, A. W., Ward, K. C., Hamilton, A. S., Deapen, D. M., Abrahamse, P., Bondarenko, I., Li, Y., Hawley, S. T., Morrow, M., Jagsi, R., & Katz, S. J. (2018). Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.0644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.